Mediso Medical Imaging Systems

What Mediso Medical Imaging Systems does

Mediso Medical Imaging Systems (Mediso Kft.) is a privately held, 100% Hungarian-owned medical imaging equipment manufacturer founded in 1990 and headquartered in Budapest. The company designs, manufactures, and sells clinical and preclinical nuclear medicine and molecular imaging systems, with a portfolio spanning SPECT, PET, CT, and MRI — most notably hybrid and multi-modality configurations such as SPECT/CT, PET/CT, PET/MRI (3T and 7T), and triple-modality SPECT/CT/PET. Its clinical platform is branded AnyScan (with products like the AnyScan TRIO-TheraMAX SPECT/CT for theranostic imaging and the AnyScan DUO SPECT/CT for routine use), and its preclinical platform is branded nanoScan. Underpinning the hardware is the proprietary Tera-Tomo 3D Monte Carlo reconstruction engine, the InterView software platform (FDA-approved for PET/SPECT/MRI/CT processing), and a set of differentiated technology building blocks including SmartMagnet cryogen-free superconducting magnets, multi-pinhole collimators, RoboCart automated collimator exchange, and AI-Powered Synthetic CT (SyCT) for zero-dose attenuation correction.

The company sells high-ticket capital equipment through a direct enterprise field sales motion supported by wholly-owned subsidiaries in Hungary (HQ), the USA, Germany, Poland, Belgium, France, and the UK, covering hospitals, clinics, and scientific research institutions across Europe, North America, and select rest-of-world markets (Australia). Revenue is generated primarily through hardware sales of imaging systems, augmented by subscription/recurring software and service contracts (InterView platform and ongoing service). Named reference customers include University Hospital Regensburg, Heidelberg University Hospital, Northeastern University's Center for Translational NeuroImaging, and ScanoMed Nuclear Medicine Centers — all deploying Mediso systems for theranostics, radiopharmaceutical therapy dosimetry, and advanced neuroscience research. Mediso is led by Managing Director István Bagaméry and has grown to more than 300 employees at its Budapest headquarters.

The business model is classic high-value medical capital equipment: long, consultative sales cycles, high average selling prices per system, recurring service and software revenue, and a horizontal segmentation strategy targeting both clinical (hospitals/clinics) and preclinical (academic, pharma, CRO) buyers. The company is actively expanding — establishing new European subsidiaries (France in 2025, Belgium in 2022, UK in 2023), acquiring regional players (Bartec Technologies, 2022), and launching new products aligned with the rapidly growing radioligand theranostics market.

Name

Mediso Medical Imaging Systems

Legal name

Mediso Kft.

Website

https://mediso.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)

akta.pro secondary industry

Computed Tomography (CT) Systems (HLAHABAB)

Keywords

• Nuclear medicine imaging
• Molecular imaging systems
• SPECT CT imaging
• PET MRI systems
• Preclinical imaging equipment

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Medical Imaging Equipment Sales: Sale of clinical and preclinical nuclear medicine and molecular imaging systems including SPECT/CT, PET/CT, PET/MRI, and MRI equipment
2. Software and Service Contracts: InterView™ software platform for image processing and reconstruction, workflow servers, and ongoing service/support contracts

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Mediso Medical Imaging Systems designs, manufactures, and sells clinical and preclinical molecular imaging systems that combine SPECT, PET, CT, and MRI modalities. The portfolio includes the AnyScan clinical platform (SPECT/CT, SPECT/CT/PET) and the nanoScan preclinical platform (PET/MRI, SPECT/CT, PET/CT), along with InterView multimodality image processing software and the proprietary Tera-Tomo 3D reconstruction engine. Systems are sold to hospitals, clinics, and scientific research institutions worldwide through wholly-owned regional subsidiaries.

Product overview

Mediso Medical Imaging Systems is a medical imaging technology company founded in 1990 with headquarters in Budapest, Hungary, offering a comprehensive portfolio of clinical and preclinical molecular imaging systems. The clinical product platform (AnyScan) delivers multi-modality nuclear medicine imaging systems including the TRIO-TheraMAX SPECT/CT for theranostic applications, TRIO SPECT/CT/PET triple-modality systems, and DUO SPECT/CT for routine clinical use. The preclinical product platform (nanoScan) provides molecular imaging systems for research including PET/MRI (3T and 7T), SPECT/CT, PET/CT, and SPECT/CT/PET combinations with absolute quantification. Supporting software includes InterView FUSION and InterView XP (FDA-approved multimodality image processing), InterView Workflow Server, and the proprietary Tera-Tomo 3D reconstruction engine. Recent innovations include the TRIO-TheraMAX with AI-powered Synthetic CT (SyCT), RoboCart automated collimator exchanger, and cryogen-free MRI technology across both platforms.

Differentiator

Problem solved

Functional benefit

Brands

• AnyScan: Clinical product platform delivering multi-level NM imaging systems with modality and detector combinations, including SPECT, SPECT/CT, and SPECT/CT/PET configurations
• nanoScan
• InterView
• Tera-Tomo
• SmartMagnet
• RoboCart
• SyCT

Products and services

• AnyScan TRIO-TheraMAX SPECT/CT High-performance clinical SPECT/CT system for theranostic and diagnostic imaging with 15.9 mm NaI crystals, triple-detector 360° coverage, and ultra-fast quantitative total-body scans for radioisotopes used in targeted radionuclide therapies. Designed for clinical nuclear medicine departments, hospitals, and theranostic centers.
• AnyScan TRIO SPECT/CT/PET Integrated triple-detector SPECT/CT and PET/CT system in a single-room installation with cost-optimized return on investment and unified workflow for clinical nuclear medicine imaging. Targeted at clinical sites seeking triple-modality imaging in one room.
• AnyScan DUO SPECT/CT Complete solution for daily routine nuclear medicine imaging covering hybrid SPECT/CT applications with dual-detector configuration. Targeted at hospitals and clinics performing routine diagnostic nuclear medicine.
• nanoScan PET/MRI 3T and 7T Full-scale quantitative preclinical PET combined with cryogen-free superconducting MRI at 3T or 7T field strength. Features dual PET configuration (in-line and insert), simultaneous or sequential imaging, and supports mouse, rat, marmoset, and guinea pig imaging. Designed for neuroscience, pharmaceutical, and academic research institutions.
• nanoScan SPECT/CT Versatile preclinical SPECT/CT system with absolute quantification, spatial resolution down to 0.3 mm in vivo, patented multi-pinhole collimator technology, theranostic imaging capability, and full stationary dynamic SPECT acquisition. Targeted at preclinical research laboratories.
• nanoScan PET/CT Real dynamic preclinical PET system designed for quantitative studies with 700 μm spatial resolution, ultra-fast electronics, and quantification from 60 Bq to 80 MBq. Features Tera-Tomo 3D iterative reconstruction with real-time Monte Carlo simulation.
• nanoScan MRI 3T/7T High-end preclinical MRI with cryogen-free superconducting magnet at 3T or 7T field strength. Features back-mounted cryocooler for reduced vibrations, extensive pulse sequence library including fMRI and DTI, and SmartMagnet technology for safe operation. Designed for preclinical research environments.
• nanoScan SPECT/CT/PET Triple-modality preclinical system combining SPECT, CT, and PET for comprehensive molecular imaging in a single session. Targeted at research laboratories requiring multi-tracer and multi-modality studies.
• MultiScan LFER 150 PET/CT Submillimeter resolution PET/CT system dedicated for non-human primate (NHP) imaging. Targeted at translational research and primate imaging laboratories.
• InterView FUSION FDA-approved multimodality (PET/SPECT/MRI/CT) image processing and reporting software enabling image fusion and analysis across different imaging modalities. Sells alongside Mediso clinical imaging systems for clinical reporting workflows.
• InterView XP FDA-approved multimodality processing software for PET, SPECT, MRI, and CT image processing and reporting, providing unified workflow across Mediso clinical imaging systems.

Quantifiable outcome

• 300% sensitivity gain compared to dual-detector systems for TheraMAX
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

One partnership is on record.

• Bartec Technologies Ltd.coreStrategic or Co-development Partner · 4 May 2022Acquisition of UK-based Bartec Technologies Ltd., a company specializing in nuclear medicine and molecular imaging equipment. This acquisition strengthened Mediso's market position in the UK and Ireland and enhanced relationships with existing and prospective customers. Mediso Medical Imaging Systems UK Ltd. was established in 2023.

Scale indicators4 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• Siemens Healthineers: Global medical imaging leader with broad SPECT, PET, CT, MRI and hybrid imaging portfolios. Directly competes with Mediso's AnyScan nuclear medicine line while also offering adjacent modalities, informatics, and enterprise hospital contracts that Mediso cannot match.
• GE HealthCare: Major incumbent in molecular imaging with SPECT, PET/CT and PET/MRI offerings (Discovery, Omni Legend) plus integrated pharmaceutical diagnostics. Competes head-to-head in nuclear medicine hospital sales while operating across the full imaging value chain.
• Philips: Diversified imaging and health technology company with SPECT/CT, PET/CT and PET/MRI systems. Overlaps with Mediso in clinical nuclear medicine while offering broader patient monitoring, ultrasound, and enterprise informatics.
• Canon Medical Systems: Imaging incumbent with SPECT, PET/CT, CT and MRI product lines serving hospitals globally. Comparable to Mediso in nuclear medicine hardware, but operates across a much wider modality portfolio.

Emerging players

• United Imaging Healthcare: Fast-growing Chinese imaging equipment maker with PET/CT, PET/MRI, and MRI systems now expanding in Europe and the US. Targets the same hospital procurement budgets as Mediso with a broader modality portfolio at competitive price points.
• Cubresa: Preclinical PET insert maker that integrates into third-party MRI systems. Competes with Mediso's nanoScan PET/MRI platform in the preclinical molecular imaging market, particularly for translational neuroscience research.
• Aspect Imaging: Preclinical compact MRI system maker with cryogen-free designs. Overlaps with Mediso's preclinical MRI offering, particularly in small-animal and benchtop research imaging applications.
• Molecubes: Preclinical molecular imaging company offering modular benchtop PET, SPECT and CT 'cubes' for academic and pharma research. Competes with Mediso's nanoScan line for translational and small-animal imaging budgets.

Direct peers

• Bruker: Preclinical imaging and lab instrumentation company with PET, SPECT, MRI and microCT systems. Directly competes with Mediso's nanoScan preclinical platform in academic and pharma research accounts.
• MR Solutions: Preclinical MRI specialist known for cryogen-free superconducting magnets, directly overlapping with Mediso's nanoScan MRI 3T/7T positioning. Competes for the same preclinical research lab customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/MedisoHungary
• LinkedInlinkedin.com/company/mediso-medical-imaging-systems

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mediso Medical Imaging Systems